Co-mutation of PCLO and SYNE1 defines an immune-activated endometrial cancer subtype with favorable prognosis

IF 1.5 4区 医学 Q3 OBSTETRICS & GYNECOLOGY
Caihong Wu, Dongmei Han, Xin Li, Dan Wang, Hao Jin
{"title":"Co-mutation of PCLO and SYNE1 defines an immune-activated endometrial cancer subtype with favorable prognosis","authors":"Caihong Wu,&nbsp;Dongmei Han,&nbsp;Xin Li,&nbsp;Dan Wang,&nbsp;Hao Jin","doi":"10.1111/jog.70077","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Endometrial cancer (EC) is a genomically heterogeneous malignancy with diverse immune microenvironment profiles. Although POLE mutations and MSI-H status are established predictors of immunotherapy response, additional composite biomarkers that integrate mutational burden and immune activation are needed. PCLO and SYNE1 are frequently mutated structural genes in EC, yet their cooperative significance remains unknown.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We analyzed 505 EC cases from The Cancer Genome Atlas (TCGA) and 95 additional samples from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), stratifying tumors based on PCLO and SYNE1 mutation status. Genomic, transcriptomic, immunologic, and clinical features were compared between co-mutation and non-co-mutation groups. Differential expression gene and pathway enrichment were conducted to identify immune-related transcriptional programs. Survival analysis and nomogram were performed to assess prognostic impact.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>PCLO and SYNE1 co-mutation defined a notable EC subtype with significant enrichment of POLE mutations, high tumor mutation burden (TMB), reduced aneuploidy, and elevated MSIsensor scores. Clinically, the overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) of the co-mutation group was significantly improved. Moreover, the co-mutation group exhibited increased infiltration of CD8<sup>+</sup> T cells, M1 macrophages, and activated CD4<sup>+</sup> memory T cells, as well as upregulation of immune checkpoint genes and chemokine signaling pathways. Finally, a nomogram incorporating co-mutation status outperformed conventional prognosticators and demonstrated high accuracy in survival prediction.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PCLO and SYNE1 co-mutation identifies a biologically distinct EC subset with heightened immunogenicity and superior prognosis. The co-mutation may serve as a robust, integrative biomarker for immune responsiveness and risk stratification in EC.</p>\n </section>\n </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 9","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436211/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynaecology Research","FirstCategoryId":"3","ListUrlMain":"https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.70077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Endometrial cancer (EC) is a genomically heterogeneous malignancy with diverse immune microenvironment profiles. Although POLE mutations and MSI-H status are established predictors of immunotherapy response, additional composite biomarkers that integrate mutational burden and immune activation are needed. PCLO and SYNE1 are frequently mutated structural genes in EC, yet their cooperative significance remains unknown.

Methods

We analyzed 505 EC cases from The Cancer Genome Atlas (TCGA) and 95 additional samples from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), stratifying tumors based on PCLO and SYNE1 mutation status. Genomic, transcriptomic, immunologic, and clinical features were compared between co-mutation and non-co-mutation groups. Differential expression gene and pathway enrichment were conducted to identify immune-related transcriptional programs. Survival analysis and nomogram were performed to assess prognostic impact.

Results

PCLO and SYNE1 co-mutation defined a notable EC subtype with significant enrichment of POLE mutations, high tumor mutation burden (TMB), reduced aneuploidy, and elevated MSIsensor scores. Clinically, the overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) of the co-mutation group was significantly improved. Moreover, the co-mutation group exhibited increased infiltration of CD8+ T cells, M1 macrophages, and activated CD4+ memory T cells, as well as upregulation of immune checkpoint genes and chemokine signaling pathways. Finally, a nomogram incorporating co-mutation status outperformed conventional prognosticators and demonstrated high accuracy in survival prediction.

Conclusions

PCLO and SYNE1 co-mutation identifies a biologically distinct EC subset with heightened immunogenicity and superior prognosis. The co-mutation may serve as a robust, integrative biomarker for immune responsiveness and risk stratification in EC.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

Abstract Image

PCLO和SYNE1的共突变定义了一种预后良好的免疫激活子宫内膜癌亚型。
背景:子宫内膜癌(EC)是一种具有不同免疫微环境特征的基因组异质性恶性肿瘤。虽然POLE突变和MSI-H状态是免疫治疗反应的确定预测因素,但还需要其他结合突变负担和免疫激活的复合生物标志物。PCLO和SYNE1是EC中经常发生突变的结构基因,但它们的协同作用尚不清楚。方法:我们分析了来自癌症基因组图谱(TCGA)的505例EC病例和临床蛋白质组学肿瘤分析联盟(CPTAC)的95例额外样本,根据PCLO和SYNE1突变状态对肿瘤进行分层。比较共突变组和非共突变组的基因组学、转录组学、免疫学和临床特征。通过差异表达基因和途径富集鉴定免疫相关转录程序。采用生存分析和nomogram来评估预后影响。结果:PCLO和SYNE1共突变定义了一个显著的EC亚型,其极突变显著富集,肿瘤突变负担(TMB)高,非整倍体减少,mssensor评分升高。临床方面,共突变组的总生存期(OS)、无进展生存期(PFS)、无病生存期(DFS)均有显著改善。此外,共突变组表现出CD8+ T细胞、M1巨噬细胞和活化CD4+记忆T细胞的浸润增加,免疫检查点基因和趋化因子信号通路上调。最后,结合共突变状态的nomogram (nomogram)优于传统的预测方法,在生存预测中表现出较高的准确性。结论:PCLO和SYNE1共突变确定了一个生物学上独特的EC亚群,具有增强的免疫原性和良好的预后。该共突变可以作为EC中免疫反应性和风险分层的一个强大的、综合的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
376
审稿时长
3-6 weeks
期刊介绍: The Journal of Obstetrics and Gynaecology Research is the official Journal of the Asia and Oceania Federation of Obstetrics and Gynecology and of the Japan Society of Obstetrics and Gynecology, and aims to provide a medium for the publication of articles in the fields of obstetrics and gynecology. The Journal publishes original research articles, case reports, review articles and letters to the editor. The Journal will give publication priority to original research articles over case reports. Accepted papers become the exclusive licence of the Journal. Manuscripts are peer reviewed by at least two referees and/or Associate Editors expert in the field of the submitted paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信